Regeneron Q2 revenue $3.68B (+4%), GAAP EPS $12.81, non-GAAP EPS $12.89; Dupixent sales +22%

REGENERON PHARMACEUTICALS, INC.

2025-Q2 EPS reported $20.02 revenue$6,704,300,000

Revenue $3.676B (+4% YoY); GAAP net income $1.392B, GAAP EPS $12.81 (+3%); non-GAAP EPS $12.89 (+12%).
Dupixent global net sales (Sanofi) up 22% to $4.34B; EYLEA HD U.S. net sales up 29% to $393M, total EYLEA U.S. down 25% to $1.15B.
FDA approved Lynozyfic (linvoseltamab) for relapsed/refractory multiple myeloma and Dupixent for bullous pemphigoid and chronic spontaneous urticaria.
EYLEA HD PDUFA delayed due to FDA filler inspection; odronextamab received CRL; company expects expeditious resolution.
In-licensed late-stage dual GLP-1/GIP agonist from Hansoh; Q2 share repurchases $1.07B; $0.88 dividend declared.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.